Application of MicroRNA of plasma exosome as marker in development of Meige syndrome screening product

By detecting the expression of miR-744-5p and miR-328-3p in plasma exosomes, the problem of lack of specific diagnostic markers in Meige syndrome is solved, and a high sensitivity and specific auxiliary diagnosis is achieved, providing An effective screening tool.

CN118910246APending Publication Date: 2024-11-08BEIJING HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411158634.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Meige syndrome lacks specific diagnostic biomarkers, resulting in difficulty in diagnosis and misdiagnosis.

Method used

By detecting the expression of miR-744-5p and miR-328-3p in plasma exosomes, using PCR kits and auxiliary diagnostic devices, combined with data acquisition, judgment and output modules, auxiliary diagnostic tools are provided to screen for Meige syndrome using PCR kits and auxiliary diagnostic devices. .

Benefits of technology

The expression levels of miR-328-3p and miR-744-5p show high sensitivity and specificity, which can effectively assist in the diagnosis of Meige syndrome, providing potential biomarkers to improve diagnostic accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005005799590000031
    Figure BDA0005005799590000031
  • Figure BDA0005005799590000041
    Figure BDA0005005799590000041
  • Figure BDA0005005799590000051
    Figure BDA0005005799590000051
Patent Text Reader

Abstract

The invention discloses an application of MicroRNA (Ribonucleic Acid) of a plasma exosome as a marker in developing a Meige syndrome screening product. The invention provides an application of a substance for detecting the expression quantity of plasma exosome miR-744-5p or miR-328-3p in preparation of a product for auxiliary diagnosis or screening or auxiliary screening of Meige syndrome. According to the invention, exosomes are separated from 68 plasma samples by using an ultracentrifugation method, and hsa-miR-328-3p and hsa-miR-744-5p are found to be up-regulated in the exosomes of a patient, so that hsa-miR-328-3p and hsa-miR-744-5p can be possibly used as diagnostic tools for Meige syndrome. Then, the diagnosis efficacy of potential biomarkers miR-328-3p and miR-744-5p is verified and evaluated by using qPCR (Quantitative Polymerase Chain Reaction), the expression levels of the miR-328-3p and miR-744-5p show relatively good sensitivity and specificity, and the miR-328-3p and miR-744-5p are used for clinical diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to the application of plasma exosome MicroRNA as a marker in the development of Meige syndrome screening products. Background Art

[0002] Meige syndrome was first reported by Henry Meige in 1910. It is a segmental dystonia characterized by blepharospasm and oromandibular dystonia, usually occurring between the ages of 30 and 70. Persistent abnormal contraction of facial muscles can lead to visual impairment, chewing and language dysfunction, and psychological complications, seriously affecting patients' daily lives. Causes include genetic and environmental factors. Patients have abnormal basal ganglia circuits and neurotransmitter disorders. The diagnosis of Meige syndrome relies on a professional physician's assessment of the patient's medical history and clinical manifestations. Laboratory tests and imaging cannot identify Meige syndrome. The lack of technical diagnostic tools means that Meige syndrome is often misdiagnosed. There are currently no specific diagnostic biomarkers.

[0003] Exosomes are extracellular microvesicles with a diameter range of 30 to 150 nm. They are widely distributed in body fluids such as blood, saliva, urine, and cerebrospinal fluid, and are involved in intercellular transport and communication. MicroRNAs (miRNAs) are a conserved non-coding RNA molecule with a length of about 22 nucleotides. miRNAs have different expression levels under different pathological and physiological conditions, so they can be used as biomarkers for disease diagnosis and prognosis. MiRNAs in exosomes can pass through the blood-brain barrier and enter the systemic circulation, providing a unique window for the study of central nervous system diseases. Summary of the invention

[0004] The purpose of the present invention is to provide the application of plasma exosome MicroRNA as a marker in the development of Meige syndrome screening products.

[0005] In a first aspect, the present invention provides the use of a substance for detecting the expression level of miR-744-5p and / or miR-328-3p in plasma exosomes in the preparation of a product for auxiliary diagnosis or screening or auxiliary screening of Meige syndrome.

[0006] In the application described above, the nucleotide sequence of miR-744-5 is sequence 2, and the nucleotide sequence of miR-328-3p is sequence 1.

[0007] In the above application, the substance for detecting the expression of miR-744-5p and / or miR-328-3p in plasma exosomes is any one of the following:

[0008] 1) comprising a primer pair and a probe for amplifying miR-744-5p and / or miR-328-3p;

[0009] 2) A PCR reagent or kit containing the primer pair and the probe.

[0010] In the application described above, the primer pair and probe for amplifying the miR-328-3p gene are composed of the single-stranded DNA molecule shown in sequence 3, the single-stranded DNA molecule shown in sequence 4, and the single-stranded DNA molecule shown in sequence 5;

[0011] The primer pair and probe for amplifying miR-744-5p are composed of the single-stranded DNA molecule shown in sequence 6, the single-stranded DNA molecule shown in sequence 7 indicated The single-stranded DNA molecule is composed of the single-stranded DNA molecule shown in sequence 8.

[0012] In a second aspect, the present invention provides a kit for assisting in the diagnosis of Meige syndrome, comprising the substance for detecting the expression levels of miR-744-5p and miR-328-3p in plasma exosomes as described in the first aspect.

[0013] In a third aspect, the present invention provides a device for assisting in the diagnosis of Meige syndrome, comprising a data acquisition module, a threshold acquisition module, a judgment module and an output module;

[0014] The data acquisition module is used to obtain the expression level of miR-744-5p or the expression level of miR-328-3p in the plasma exosomes of the subjects and the healthy controls;

[0015] The judgment module is used to compare the expression level of miR-744-5p or the expression level of miR-328-3p in the plasma exosomes of the subject and the healthy control to obtain a judgment result.

[0016] The output module is used to output the judgment result obtained by the judgment module.

[0017] In a fourth aspect, the present invention provides a product for assisting in the diagnosis of Meige syndrome, comprising the substance for detecting the expression level of plasma exosome miR-744-5p and / or miR-328-3p in the first aspect, the kit described in the second aspect, or the device described in the third aspect.

[0018] In a fifth aspect, the present invention provides the use of the substance for detecting the expression level of miR-744-5p and / or miR-328-3p in plasma exosomes described in the first aspect, the kit described in the second aspect, or the device described in the third aspect in the preparation of auxiliary diagnosis or screening or auxiliary screening products for Meige syndrome.

[0019] The present invention uses ultracentrifugation to separate exosomes from 68 plasma samples, and uses next-generation sequencing (NGS) to compare the expression profiles of plasma exosome miRNAs in patients with Meige syndrome and healthy controls. It was found that hsa-miR-328-3p and hsa-miR-744-5p were upregulated in the exosomes of patients and may be used as a diagnostic tool for Meige syndrome. Then, several differentially expressed miRNAs (DEmiRNAs) were verified using qPCR, and the diagnostic efficacy of potential biomarkers miR-328-3p and miR-744-5p was further evaluated in order to provide a reference for clinical application. The results showed that the expression levels of miR-328-3p and miR-744-5p showed good sensitivity and specificity. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The results of high-throughput sequencing of exosomal miRNAs; Volcano plot of miRNAs in patients with Meige syndrome compared with healthy controls. Each point represents a miRNA.

[0021] Figure 2 The relative expression levels of hsa-miR-584-5p (A), hsa-miR-744-5p (B), and hsa-miR-328-3p (C) detected by PCR, and the ROC curves of hsa-miR-584-5p (D), hsa-miR-744-5p (E), and hsa-miR-328-3p (F).

[0022] Figure 3 For the overall research process. DETAILED DESCRIPTION

[0023] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0024] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0025] The subjects in the following examples are as follows:

[0026] A total of 36 patients with Meige syndrome and 32 sex / age-matched healthy controls were enrolled. Patients underwent rigorous neurological examinations and were diagnosed by at least two experienced neurologists according to the criteria described by Pakkenberg et al. Exclusion criteria included a history of other neurological diseases (cerebral trauma, intracranial tumors, cerebrovascular disease, encephalitis, or Parkinson's disease), a history of severe mental illness or cognitive impairment, and MRI of the brain showing qualitative lesions or dystonia involving other parts of the body. Although some patients had received oral medications or local injections of botulinum toxin type A, all patients still had significant symptoms.

[0027] The demographic and clinical characteristics of the patients, including the course of the disease and the BFMDRS scores, are shown in Table 2. All patients with Meige syndrome showed significant blepharospasm. Of these, 83% had oromandibular dystonia, and 42% had varying degrees of cervical dystonia.

[0028] The statistical analysis method in the following embodiments is as follows:

[0029] Normality was verified using the Shapiro-Wilk test. Differences between groups were analyzed using the Student's t test or the Mann-Whitney U test. Normally distributed data were presented as mean ± standard error (SEM), and non-normally distributed data were presented as median. A p value < 0.05 was considered statistically significant. The obtained P values ​​were adjusted using the method of Benjamini and Hochberg to control the false discovery rate (FDR).

[0030] Example 1. Discovery of diagnostic markers for Meige syndrome

[0031] 1. Isolation and NGS analysis of plasma exosome miRNA

[0032] Exosomes were extracted from the plasma of 12 patients with Meige syndrome and 12 healthy controls (specific phenotypes of the subjects are shown in Table 1) (venous blood samples were collected by conventional venipuncture in ethylenediaminetetraacetic acid (EDTA) tubes and ultracentrifuged), and nanoparticle tracking analysis (NTA) and western blot analysis were used to identify exosomes.

[0033] miRNAs were extracted from individual plasma exosomes using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Small RNA libraries were generated using the NEB Next Multiplex small RNA library Prep Set for Illumina (New England Biolabs, Ipswich, MA, USA).

[0034] The edgeR R package was used to perform differential expression analysis between the two samples, with a significance threshold of p < 0.05 and |foldchange| ≥ 1.5. miRanda and RNAhybrid were used to predict the target genes of DEmiRNAs.

[0035] Table 1 shows the clinical characteristics

[0036]

[0037] MS, Meige syndrome; BFMDRS, Burk-Fahn-Marsden Dystonia Rating Scale; M, male; F, female. p1, NGS healthy controls vs PCR healthy controls; p2, NGS MS patients vs PCR MS patients.

[0038] Deep sequencing of samples from 12 Meige syndrome patients and 12 healthy controls revealed Figure 1 As shown, the results of high-throughput sequencing of exosomal miRNAs, volcano plot of miRNAs in patients with Meige syndrome compared with healthy controls, each dot represents a miRNA. Through sequence alignment, 1035 miRNAs were obtained from the samples, including 1020 known and 15 newly predicted miRNAs. Compared with the control group, 43 miRNAs were upregulated and 6 miR-RNAs were downregulated in the patient group. There were no significant differences in gender composition and age between sequencing subjects and PCR subjects in the patient group and the healthy control group.

[0039] According to the fold changes and P values, three upregulated DEmiRNAs (hsa-miR-328-3p, hsa-miR-744-5p, and hsa-miR-584-5p) and two downregulated DEmiRNAs (hsa-mir-205-5p and hsa-miR-342-5p) shown in Table 2 were selected as candidate screening or diagnostic markers for Meige syndrome patients for further validation by qPCR.

[0040] Table 2 shows the markers obtained by NGS

[0041]

[0042] P value and Log2FC are the comparison results of sequencing data between Meige syndrome group and control group. Ct min and Ct Max represent the minimum and maximum value of qPCR threshold cycle number, respectively.

[0043] 2. PCR validation of diagnostic markers for Meige syndrome

[0044] Exosomes were extracted from the plasma of 20 patients with Meige syndrome and 24 healthy controls (specific subject phenotypes are shown in Table 2).

[0045] miRNAs were extracted from each plasma exosome using the miRNeasy Mini Kit (Qiagen, Hilden, Germany), and the cDNA obtained by reverse transcription was used as a template for quantitative polymerase chain reaction using the primers shown in Table 3. -△△Ct Methods The relative expression levels of five miRNAs were calculated, with U6 as the internal reference.

[0046] The reverse transcription system (LC-480; Roche, Santa Clara, CA, USA) was used. The reverse transcription premix consisted of 6 μL 5× RT buffer, 21 μL RNA, 1.5 μL RT primer mix, and 1.5 μL RT enzyme. The reaction was incubated at 37°C for 60 min, 85°C for 5 s, and 4°C for 60 min. The qPCR reaction consisted of 10 μL 2× qPCR Buffer, 2 μL Primer Mix, 3 μL template cDNA, and 5 μL ddH2O in a total volume of 20 μL. The reaction was incubated at 95°C for 30 s, followed by 50 cycles of incubation at 95°C for 5 s and 58°C for 30 s. All reactions were performed three times. The primer sequences are shown in Table 3.

[0047] Table 3 shows the PCR primers

[0048]

[0049] The results of hsa-miR-328-3p, hsa-miR-744-5p and hsa-miR-584-5p are as follows Figure 2 As shown in A-2C, it can be seen that the expression levels of hsa-miR-328-3p and hsa-miR-744-5p are upregulated in patients with Meige syndrome, which is consistent with the sequencing data. However, qPCR showed that there was no significant difference in the expression level of hsa-miR-584-5p in patients with Meige syndrome. This is inconsistent with the upregulation trend shown by the sequencing results.

[0050] In addition, the expression of hsa-miR-204-5p and hsa-miR-342-5p was relatively low, with a median Ct value greater than 35, and no further analysis was performed.

[0051] Therefore, hsa-miR-328-3p and hsa-miR-744-5p can be used as screening or diagnostic markers for patients with Meige syndrome.

[0052] Nucleotide sequence of hsa-miR-328-3p: CUGGCCCUCUCUGCCCUUCCGU (SEQ ID NO: 1)

[0053] Nucleotide sequence of hsa-miR-744-5p: UGCGGGGCUAGGGCUAACAGCA (sequence 2)

[0054] Nucleotide sequence of hsa-miR-584-5p: UUAUGGUUUGCCUGGGACUGAG

[0055] 3. ROC curve validation of miR-328-3p and miR-744-5p as diagnostic markers for Meige syndrome

[0056] The relative expression levels of hsa-miR-328-3p, hsa-miR-744-5p and hsa-miR-584-5p in plasma exosomes of 20 patients with Meige syndrome and 24 healthy controls obtained above were used to construct the receiver operating characteristic curve (ROC) and calculate the area under the curve (AUC) to evaluate the diagnostic value of exosomal hsa-miR-328-3p, hsa-miR-744-5p and hsa-miR-584-5p as biomarkers for Meige syndrome. The optimal sensitivity and specificity were determined by the Youden index.

[0057] The results are as follows Figure 2 As shown in D-2F, the ROC curve analysis data showed that compared with hsa-miR-584-5p, the AUC values ​​of hsa-miR-328-3p (95% CI -0.642-0.933, AUC -0.788, p < 0.001) and hsa-miR-744-5p (95% CI = 0.648-0.935, AUC -0.792, p < 0.001) were close to 1, with high sensitivity and specificity (hsa-miR-584-5p sensitivity 75% specificity 65%, hsa-miR-328-3p sensitivity 79.17% specificity 85%, hsa-miR-744-5p sensitivity 79.17% specificity 85%).

[0058] Therefore, combined with PCR and ROC curve validation, hsa-miR-328-3p and hsa-miR-744-5p were identified as candidate biomarkers for the diagnosis or screening of Meige syndrome.

[0059] The specific method of using the marker to diagnose or assist in the diagnosis or screening or assist in the screening of patients with Meige syndrome is as follows:

[0060] Detect the relative expression of miR-328-3p or miR-744-5p in the plasma exosomes of the subjects;

[0061] If the expression of miR-328-3p or miR-744-5p in the subject is greater than that in the healthy control sample, the subject is or is a candidate for being a patient with Meige syndrome;

[0062] If the expression level of miR-328-3p or miR-744-5p in the subject is less than or equal to that in the healthy control sample, the subject is not or is not a candidate for being a patient with Meige syndrome.

[0063] The above-mentioned subject may be a patient suspected of Meige syndrome.

[0064] The relative expression level of miR-328-3p or miR-744-5p is relative to the expression level of U6 gene, and the primer sequences for detecting the expression level are as shown in Sequence 3, Sequence 4 and Sequence 5, or Sequence 6, Sequence 7 and Sequence 8 in Table 3.

[0065] Figure 3 For the overall research process.

Claims

1. Use of substances for detecting the expression of miR-744-5p and / or miR-328-3p in plasma exosomes in the preparation of products for auxiliary diagnosis or screening or auxiliary screening of Meige syndrome.

2. The use according to claim 1, characterized in that: The substance for detecting the expression of miR-744-5p and / or miR-328-3p in plasma exosomes is any one of the following: 1) comprising a primer pair and a probe for amplifying miR-744-5p and / or miR-328-3p; 2) A PCR reagent or kit containing the primer pair and the probe.

3. The use according to claim 2, characterized in that: The primer pair and probe for amplifying miR-328-3p are composed of the single-stranded DNA molecule shown in sequence 3, the single-stranded DNA molecule shown in sequence 4, and the single-stranded DNA molecule shown in sequence 5; The primer pair and probe for amplifying miR-744-5p consist of the single-stranded DNA molecule shown in sequence 6, the single-stranded DNA molecule shown in sequence 7, and the single-stranded DNA molecule shown in sequence 8.

4. A kit for assisting the diagnosis of Meige syndrome, comprising the substance for detecting the expression level of miR-744-5p and / or miR-328-3p in plasma exosomes as described in any one of claims 1 to 3.

5. A device for assisting diagnosis of Meige syndrome, comprising a data acquisition module, a threshold acquisition module, a judgment module and an output module; The data acquisition module is used to obtain the expression level of miR-744-5p or the expression level of miR-328-3p in the plasma exosomes of the subjects and the healthy controls; The judgment module is used to compare the expression level of miR-744-5p or the expression level of miR-328-3p in the plasma exosomes of the subject and the healthy control to obtain a judgment result. The output module is used to output the judgment result obtained by the judgment module.

6. A product for assisting the diagnosis of Meige syndrome, comprising the substance for detecting the expression level of miR-744-5p and / or miR-328-3p in plasma exosomes as described in any one of claims 1 to 3, the kit as described in claim 4, or the device as described in claim 5.

7. Use of the substance for detecting the expression level of miR-744-5p and / or miR-328-3p in plasma exosomes according to any one of claims 1 to 6, the kit according to claim 4, or the device according to claim 5 in the preparation of a product for auxiliary diagnosis or screening or auxiliary screening of Meige syndrome.